NF-kB SUBUNITS p65 AND RelB IN OSTEOCLASTS
破骨细胞中的 NF-kB 亚基 p65 和 RelB
基本信息
- 批准号:7196934
- 负责人:
- 金额:$ 30.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-15 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Osteoclasts (OCs) are critical for calcium homeostasis and structural bone integrity, but their inappropriate activation is responsible for significant morbidity in many diseases, including osteoporosis, rheumatoid arthritis, and cancer metastasis to bone. RANKL mediates differentiation of macrophage lineage cells into OCs and induces NF-kappaB. There are 5 subunits in the NF-kappaB family (p65, RelB, c-rel, p50, and p52) each bearing the DNA-binding Rel homology domain, and transcription is mediated by homo-and -heterodimers. Activation of NF-kappaB occurs by two distinct routes. The classical pathway involves IkappaB kinase beta (IKKbeta)-dependent degradation of IkappaBalpha and rapid translocation of active NF-kappaB dimers, primarily p65/p50, into the nucleus. Additionally, phosphorylation and acetylation of p65 occur in a signal-dependent manner, and further modulate NF-kappaB activity. The alternative pathway is controlled by NIK which activates IKKalpha, prompting generation, from its precursor p100, of the active NF-kappaB subunit p52, which travels to the nucleus with RelB over several hours and remains for days. Thus, RANKL exposure leads to both acute and prolonged activation of NF-kappaB by stimulating the classical and alternative pathways, respectively, with each controlling different heterodimers. We find that lack p65, the key transducer of the classical pathway, leads to OC precursor apoptosis, in vitro, and a decreased OC response to RANKL, in vivo. In contrast, lack of RelB, the unique subunit of the alternative pathway, blocks OC differentiation, in vitro, and diminishes pathological bone resporption, in vivo, in the absence of apoptosis. Additionally, overexpression of one subunit cannot compensate for the absence of the other subunit, indicating distinct functions for these NF-kappaB subunits. We hypothesize that: 1) in vivo, p65 controls OC differentiation and survival, and RelB controls OC differentiation, 2) specific components of the transcriptional activation (TA) and Rel homology (RH) domains of p65 and RelB confer their distinct functions in OC survival and differentiation, 3) post- translational modifications of p65 (acetylation and phosphorylation) are critical for its function downstream of RANKL. We therefore propose to: 1) define the requirements for p65 and RelB in OC differentiation and survival, in vivo, by examining the basal and RANKL-stimulated bone phenotype in mice lacking p65 or RelB, 2) determine which components of the TA and RH domains of p65 and RelB confer their distinct functions on OC survival and differentiation, 3) define the post-translational p65 acetylation and phosphorylation events that are critical for its function downstream of RANKL. Because NF-kappaB is a target of existing drugs such as the proteosome inhibitor bortezomib, and other drugs currently in development, it is critically important to understand its specific pathways in physiological contexts such as bone. We expect that this study will contribute to better rational design of drugs to target specific pathophysiology.
描述(由申请人提供):破骨细胞(OC)对于钙稳态和结构骨完整性至关重要,但其不适当的激活是导致许多疾病(包括骨质疏松症、类风湿性关节炎和癌症骨转移)显著发病的原因。RANKL介导巨噬细胞谱系细胞分化为OC并诱导NF-κ B。在NF-κ B家族中有5个亚基(p65、RelB、c-rel、p50和p52),每个亚基携带DNA结合Rel同源结构域,并且转录由同源和异源二聚体介导。NF-κ B的激活通过两种不同的途径发生。经典途径涉及IkappaB激酶β(IKK β)依赖性的IkappaB α降解和活性NF-κ B二聚体(主要是p65/p50)快速易位到细胞核中。此外,p65的磷酸化和乙酰化以信号依赖性方式发生,并进一步调节NF-κ B活性。旁路途径由NIK控制,NIK激活IKK α,促使其前体p100产生活性NF-κ B亚基p52,p52与RelB一起在数小时内进入细胞核并保留数天。因此,RANKL暴露通过分别刺激经典和旁路途径导致NF-κ B的急性和长期激活,每种途径控制不同的异源二聚体。我们发现,缺乏p65,经典途径的关键转换器,导致OC前体细胞凋亡,在体外,和降低OC响应RANKL,在体内。相反,缺乏RelB,替代途径的独特亚基,阻断OC分化,在体外,并减少病理性骨吸收,在体内,在细胞凋亡的情况下。此外,一个亚基的过表达不能补偿另一个亚基的缺失,表明这些NF-κ B亚基的不同功能。我们假设:1)在体内,p65控制OC分化和存活,RelB控制OC分化,2)p65和RelB的转录激活(TA)和Rel同源(RH)结构域的特定组分赋予其在OC存活和分化中的独特功能,3)p65的翻译后修饰(乙酰化和磷酸化)对其在RANKL下游的功能至关重要。因此,我们建议:1)通过检查缺乏p65或RelB的小鼠中的基础和RANKL刺激的骨表型,确定体内OC分化和存活中对p65和RelB的要求,2)确定p65和RelB的TA和RH结构域的哪些组分赋予OC存活和分化其不同的功能,3)定义翻译后p65乙酰化和磷酸化事件,这对其RANKL下游的功能至关重要。由于NF-κ B是现有药物(如蛋白体抑制剂硼替佐米)和目前正在开发的其他药物的靶点,因此了解其在生理环境(如骨骼)中的特定途径至关重要。我们希望这项研究将有助于更好地合理设计药物,以针对特定的病理生理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBORAH J VEIS其他文献
DEBORAH J VEIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBORAH J VEIS', 18)}}的其他基金
Musculoskeletal Histology and Morphometry Core
肌肉骨骼组织学和形态测量核心
- 批准号:
10602566 - 财政年份:2019
- 资助金额:
$ 30.18万 - 项目类别:
Musculoskeletal Histology and Morphometry Core
肌肉骨骼组织学和形态测量核心
- 批准号:
10388082 - 财政年份:2019
- 资助金额:
$ 30.18万 - 项目类别:
Role of Mitochondrial Dynamics In Bone Homeostasis
线粒体动力学在骨稳态中的作用
- 批准号:
9196224 - 财政年份:2016
- 资助金额:
$ 30.18万 - 项目类别:
IN VIVO 2-COLOR BIOLUMINESCENT IMAGING OF CLASSICAL AND ALTERNATIVE NF-KB
经典和替代 NF-KB 的体内 2 色生物发光成像
- 批准号:
7587631 - 财政年份:2008
- 资助金额:
$ 30.18万 - 项目类别:
IN VIVO 2-COLOR BIOLUMINESCENT IMAGING OF CLASSICAL AND ALTERNATIVE NF-KB
经典和替代 NF-KB 的体内 2 色生物发光成像
- 批准号:
7692919 - 财政年份:2008
- 资助金额:
$ 30.18万 - 项目类别:
NF-kB SUBUNITS p65 AND RelB IN OSTEOCLASTS
破骨细胞中的 NF-kB 亚基 p65 和 RelB
- 批准号:
7676059 - 财政年份:2006
- 资助金额:
$ 30.18万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
- 批准号:31970691
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
- 批准号:31900527
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
姜黄素与TRAIL的协同抗肿瘤机制研究
- 批准号:31101223
- 批准年份:2011
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
- 批准号:81100502
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Ing4-deficiency enhances the regenerative capacity of multipotent progenitor cells
Ing4缺陷增强多能祖细胞的再生能力
- 批准号:
10452422 - 财政年份:2022
- 资助金额:
$ 30.18万 - 项目类别:
Deciphering the histone interactions and reader functions of ASH1L in biology and leukemia
破译 ASH1L 在生物学和白血病中的组蛋白相互作用和阅读器功能
- 批准号:
10389050 - 财政年份:2022
- 资助金额:
$ 30.18万 - 项目类别:
Ing4-deficiency enhances the regenerative capacity of multipotent progenitor cells
Ing4缺陷增强多能祖细胞的再生能力
- 批准号:
10574574 - 财政年份:2022
- 资助金额:
$ 30.18万 - 项目类别:
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms
针对表观遗传和氧化应激机制的胎儿血红蛋白诱导剂的开发
- 批准号:
10602522 - 财政年份:2020
- 资助金额:
$ 30.18万 - 项目类别:
Elucidating epigenetic mechanisms of cellular cadmium toxicity
阐明细胞镉毒性的表观遗传机制
- 批准号:
10266094 - 财政年份:2020
- 资助金额:
$ 30.18万 - 项目类别:
Novel targets of the Roberts Syndrome acetyltransferase Esco2/Eco1
罗伯茨综合征乙酰转移酶 Esco2/Eco1 的新靶标
- 批准号:
10045794 - 财政年份:2020
- 资助金额:
$ 30.18万 - 项目类别:
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms
针对表观遗传和氧化应激机制的胎儿血红蛋白诱导剂的开发
- 批准号:
10385817 - 财政年份:2020
- 资助金额:
$ 30.18万 - 项目类别:
DAMP Signaling Mediates HIMF-induced Pulmonary Hypertension
DAMP 信号介导 HIMF 诱导的肺动脉高压
- 批准号:
9976575 - 财政年份:2018
- 资助金额:
$ 30.18万 - 项目类别:
DAMP Signaling Mediates HIMF-induced Pulmonary Hypertension
DAMP 信号介导 HIMF 诱导的肺动脉高压
- 批准号:
10206240 - 财政年份:2018
- 资助金额:
$ 30.18万 - 项目类别:
Mechanism-based approach to combine histone deacetylase inhibitors with PARP inhibitors for therapy in AML
基于机制的组蛋白脱乙酰酶抑制剂与 PARP 抑制剂联合治疗 AML
- 批准号:
9318753 - 财政年份:2017
- 资助金额:
$ 30.18万 - 项目类别: